Literature DB >> 21839478

Clinical aspects of impulsive compulsive behaviours in Parkinson's disease.

Atbin Djamshidian1, Bruno B Averbeck, Andrew J Lees, Sean S O'Sullivan.   

Abstract

Impulsive-compulsive behaviours (ICBs) are an increasingly well-recognised adverse-effect of dopaminergic medications used to treat Parkinson's disease. ICBs include pathological gambling, compulsive sexual behaviour, compulsive buying, and binge eating, together with punding and the addiction-like compulsive use of dopamine replacement therapy, or dopamine dysregulation syndrome. The prevalence of ICBs was approximately 14% in a large study undertaken in specialist movement disorder clinics. Dopamine dysregulation syndrome is more associated with compulsive l-dopa use, whereas other ICBs are more linked with oral dopamine agonist use. Other mechanisms implicated in the development and perpetuation of ICBs in PD include aberrant learning from reward-related situations, including decreased learning from negative feedback, increased measures of impulsivity or sensation seeking, and strong preference for immediate over future rewards. Treatment options for impulsive-compulsive behaviours include pharmacological, surgical and psychological interventions. The early recognition and prevention of ICBs, coupled with awareness of clinical risk factors for the development of these behaviours is of paramount importance, given the lack of specific treatments for these sometimes debilitating behaviours.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21839478     DOI: 10.1016/j.jns.2011.07.031

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

Review 1.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

2.  Crack cocaine use due to dopamine agonist therapy in Parkinson disease.

Authors:  Joseph H Friedman; Victoria Chang
Journal:  Neurology       Date:  2013-05-15       Impact factor: 9.910

Review 3.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

4.  Impulse control disorders in Parkinson's disease: background and update on prevention and management.

Authors:  Robert F Leeman; Benjamin E Billingsley; Marc N Potenza
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

5.  The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study.

Authors:  Pedro Barbosa; Atbin Djamshidian; Andrew J Lees; Thomas T Warner
Journal:  Mov Disord Clin Pract       Date:  2018-10-04

6.  Effects of dopamine on sensitivity to social bias in Parkinson's disease.

Authors:  Atbin Djamshidian; Sean S O'Sullivan; Andrew Lees; Bruno B Averbeck
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240

7.  Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review.

Authors:  João Massano; Carolina Garrett
Journal:  Front Neurol       Date:  2012-04-26       Impact factor: 4.003

8.  Health-related quality of life in Parkinson's disease: a cross-sectional study focusing on non-motor symptoms.

Authors:  Liis Kadastik-Eerme; Marika Rosenthal; Tiiu Paju; Mari Muldmaa; Pille Taba
Journal:  Health Qual Life Outcomes       Date:  2015-06-20       Impact factor: 3.186

9.  Electrochemical sensing method for point-of-care cortisol detection in human immunodeficiency virus-infected patients.

Authors:  Ajeet Kaushik; Adriana Yndart; Rahul Dev Jayant; Vidya Sagar; Venkata Atluri; Shekhar Bhansali; Madhavan Nair
Journal:  Int J Nanomedicine       Date:  2015-01-19

10.  Morbidity in early Parkinson's disease and prior to diagnosis.

Authors:  Rune Frandsen; Jakob Kjellberg; Rikke Ibsen; Poul Jennum
Journal:  Brain Behav       Date:  2014-04-08       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.